Last reviewed · How we verify
NAFT-600 ( naftin 2 % gel )
Naftin is an allylamine antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.
Naftin is an allylamine antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane. Used for Fungal skin infections (dermatophyte infections, tinea pedis, tinea cruris, tinea corporis).
At a glance
| Generic name | NAFT-600 ( naftin 2 % gel ) |
|---|---|
| Also known as | Naftin® |
| Sponsor | Merz North America, Inc. |
| Drug class | Allylamine antifungal |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Naftin works by inhibiting the enzyme squalene epoxidase in the sterol synthesis pathway of fungi, preventing the formation of ergosterol, a critical component of the fungal cell membrane. This disruption of membrane integrity leads to fungal cell death. The drug is effective against a broad spectrum of dermatophytes and other fungal pathogens.
Approved indications
- Fungal skin infections (dermatophyte infections, tinea pedis, tinea cruris, tinea corporis)
Common side effects
- Local skin irritation
- Burning or stinging at application site
- Erythema
- Pruritus
Key clinical trials
- Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis (PHASE3)
- Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAFT-600 ( naftin 2 % gel ) CI brief — competitive landscape report
- NAFT-600 ( naftin 2 % gel ) updates RSS · CI watch RSS
- Merz North America, Inc. portfolio CI